BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37322220)

  • 1. Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Int J Clin Oncol; 2023 Sep; 28(9):1183-1190. PubMed ID: 37322220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2022 Dec; 30(12):10203-10211. PubMed ID: 36217043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer.
    Alandağ C; Karaman E; Yüce E
    Anticancer Drugs; 2022 Apr; 33(4):389-393. PubMed ID: 35266888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
    BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
    Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
    Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
    Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
    BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.
    Goktas Aydin S; Kavak EE; Topcu A; Bayramgil A; Akgul F; Kahraman S; Aykan MB; Altıntas YE; Helvaci K; Urun Y; Bilici A; Seker M; Sendur MAN; Olmez OF; Acikgoz O; Cicin I
    Biomol Biomed; 2023 Nov; 23(6):1089-1095. PubMed ID: 37289436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Sci Rep; 2024 Mar; 14(1):5153. PubMed ID: 38431746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
    Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
    Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
    Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
    Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
    Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
    Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
    Chen J; Wang J; Lin H; Peng Y
    Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
    Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
    Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
    Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
    Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
    Ergun Y; Bal O; Dogan M; Uncu D
    J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.